Refractory Myelodysplastic Syndromes (DBCOND0134633)

Identifiers

Synonyms

Refractory Myelodysplastic Syndrome

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Ivosidenib	An isocitrate dehydrogenase-1 inhibitor used to treat acute myeloid leukemia and cholangiocarcinoma in adults with a susceptible IDH1 mutation.	Isocitrate dehydrogenase [NADP] cytoplasmictarget Cytochrome P450 3A4enzyme Cytochrome P450 2B6enzyme Cytochrome P450 2C9enzyme Cytochrome P450 2C8enzyme Organic anion transporter 3transporter ATP-dependent translocase ABCB1transporter

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT03816319	TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts	TAK-243	treatment	1	recruiting
NCT04375631	CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia	Cladribine Cyclophosphamide Cyclosporine Cytarabine Filgrastim Fludarabine Idarubicin Mitoxantrone Mycophenolate mofetil Mycophenolic acid	treatment	1	recruiting
NCT04550442	Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia	Azacitidine Venetoclax	treatment	1 / 2	recruiting
NCT01892371	Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	Azacitidine Cytarabine Quizartinib	treatment	1 / 2	completed
NCT04239157	A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients with Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia	Canakinumab	treatment	2	recruiting
NCT04874194	Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1	Omacetaxine mepesuccinate Venetoclax	treatment	1 / 2	completed
NCT06399640	Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia	Eltanexor Venetoclax	treatment	1	recruiting
NCT06484062	Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 and ASTX727 With Venetoclax to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes	Cedazuridine Cirtuvivint Decitabine Venetoclax	treatment	1	not_yet_recruiting
NCT05146739	Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane	Cytarabine Fludarabine Leucovorin Uproleselan	treatment	1	active_not_recruiting
NCT06572631	Multi-antigen Specific CD8+ T Cells with Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients with Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation from a Matched Donor	Cyclophosphamide Decitabine Fludarabine	treatment	1	not_yet_recruiting
NCT03326921	HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant	Fludarabine	treatment	1	suspended
NCT03813147	Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	Azacitidine Cytarabine Fludarabine Hydrocortisone Hydrocortisone acetate Methopterin Methotrexate Pevonedistat	treatment	1	completed
NCT06454409	Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia	Azacitidine Regorafenib Venetoclax	treatment	1	not_yet_recruiting
NCT04160052	Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome	Azacitidine Venetoclax	treatment	1 / 2	recruiting
NCT05030675	Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents	Fostamatinib	treatment	1	completed
NCT04487106	Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome	Azacitidine Trametinib Venetoclax	treatment	2	completed
NCT03772925	Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	Belinostat Pevonedistat	treatment	1	active_not_recruiting
NCT04013880	ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia	Cedazuridine Decitabine Olutasidenib	treatment	1 / 2	withdrawn
NCT02890329	Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia	Decitabine Ipilimumab	treatment	1	active_not_recruiting
NCT02392572	ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome	Dordaviprone	treatment	1 / 2	recruiting
NCT03969446	Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory	Decitabine Pembrolizumab Venetoclax	treatment	1	recruiting
NCT05564650	Evaluating Navitoclax After Failure of Standard Treatments of Azacitidine or Decitabine and Venetoclax in Patients With Aggressive Myelodysplastic Syndrome	Decitabine Navitoclax Venetoclax	treatment	1 / 2	recruiting
NCT04250051	Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia	Cytarabine Filgrastim Fludarabine Ivosidenib	treatment	1	recruiting
NCT03953898	Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation	Olaparib	treatment	2	active_not_recruiting
NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	Abemaciclib Abiraterone Afatinib Albumin human Avobenzone Bevacizumab Bicalutamide Bortezomib Bortezomib D-mannitol Cabazitaxel Cabozantinib Capecitabine Carboplatin Celecoxib Cobimetinib Copanlisib Dabrafenib Dacomitinib Darolutamide Dasatinib Daunorubicin Doxorubicin Durvalumab Enasidenib Entrectinib Enzalutamide Erlotinib Everolimus Fluorouracil Idelalisib Imatinib Ipilimumab Lenvatinib Leucovorin Lorlatinib Losartan Neratinib Nivolumab Octinoxate Olaparib Oxaliplatin Paclitaxel Palbociclib Panobinostat Pembrolizumab Pertuzumab Ponatinib Regorafenib Ruxolitinib Sirolimus Sorafenib Sunitinib Trametinib Trastuzumab emtansine Tretinoin Vemurafenib Venetoclax Vismodegib Vorinostat	treatment	1	terminated
NCT04752163	DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia	Azacitidine Coenzyme M Cortisone Cyclophosphamide Cytarabine Dexamethasone Filgrastim Leucovorin Methopterin Methotrexate Methoxamine Posaconazole Prednisone Rituximab Venetoclax Vincristine Voriconazole	treatment	1 / 2	completed
NCT04128748	Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome	Cytarabine Daunorubicin Quizartinib	treatment	1 / 2	recruiting
NCT03096782	Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma	Aloe vera leaf Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Ascorbic acid Busulfan Clofarabine Cyclophosphamide Filgrastim Fludarabine Glycerin Mechlorethamine Mycophenolate mofetil Nicotinamide Rituximab Tacrolimus Vitamin A	treatment	2	completed
NCT03630991	Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy	Edetate calcium disodium anhydrous Edetic acid Succimer	treatment	1	recruiting
NCT04623944	NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS	Cyclophosphamide Cytarabine Decitabine Fludarabine NKX101	treatment	1	active_not_recruiting
NCT04891757	FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies	Cytarabine Decitabine	treatment	1	recruiting